Clinuvel Pharmaceuticals Limited Sustainability Profile
Clinuvel Pharmaceuticals Limited, often referred to simply as Clinuvel, is an innovative biopharmaceutical company headquartered in Australia. Founded in 2002, Clinuvel has established itself as a leader in the development of treatments for skin disorders, particularly those related to UV exposure and genetic conditions. The company operates primarily in Europe, North America, and Asia, focusing on the research and commercialisation of its unique product, SCENESSE® (afamelanotide), which is designed to protect against phototoxicity. Clinuvel's commitment to advancing medical science has led to significant milestones, including regulatory approvals in multiple regions. With a strong market position, the company is recognised for its pioneering approach to photoprotection and skin health, setting it apart in the biopharmaceutical industry.
DitchCarbon Score
How does Clinuvel Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinuvel Pharmaceuticals Limited's score of 16 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinuvel Pharmaceuticals Limited's reported carbon emissions
Clinuvel Pharmaceuticals Limited, headquartered in Australia, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. Consequently, there are no recorded Scope 1, 2, or 3 emissions to analyse. Additionally, Clinuvel has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). The company has not made any climate pledges or engaged in initiatives like CDP, RE100, or CA100, which are commonly adopted by organisations aiming to enhance their sustainability practices. In the absence of specific emissions data or reduction commitments, it is unclear how Clinuvel Pharmaceuticals Limited is addressing climate change or its carbon footprint. As the industry increasingly prioritises sustainability, it will be essential for Clinuvel to consider developing measurable climate strategies and reporting frameworks to align with global standards and stakeholder expectations.
How Carbon Intensive is Clinuvel Pharmaceuticals Limited's Industry?
How Carbon Intensive is Clinuvel Pharmaceuticals Limited's Location?
Clinuvel Pharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Clinuvel Pharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
